Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Matthew I. Milowsky, MD, outlines treating bladder cancer with checkpoint inhibitors

Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, explains what physicians need to know about the progress being made treating bladder cancer with checkpoint inhibitors.

Published: 24 February 2017

Recent Videos: ASCO GU Conference Coverage

video

Jeffrey M. Holzbeierlein, MD, offers his opinion on interesting presentations from ASCO GU 2017

Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, discusses intriguing data and presentations from ASCO GU.

video

Ulka N. Vaishampayan, MD, on challenges facing patients and providers

Dr. Vaishampayan, MD, Department of Oncology, Karmanos Cancer Institute, describes the biggest challenges facing patients and providers in the diagnosis ...

video

Mohamad E. Allaf, MD, on immunotherapies and renal cell carcinoma treatment algorithms

Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, gives information ...

video

David J. McConkey, PhD, on which drugs have the highest potential to impact bladder cancer treatment

Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, gives his views on which specific drugs have ...

video

Robert B. Den, MD, discusses the recent changes in radiation treatment for invasive bladder cancer

Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, on how ...

video

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancer

Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, explains how the treatment of advanced prostate cancer ...

video

Ana Aparicio, MD, on how to sequence commonly used agents in metastatic prostate cancer

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, gives her perspective on the proper way ...

video

Neal D. Shore, MD, FACS, provides insight into data on resistance and advanced prostate cancer

Dr. Shore, MD, Director, Carolina Urologic Research Center, gives his perspective on how the treatment of advanced prostate cancer has ...

video

Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer

Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, talks about if immunotherapy will be added ...

video

Jeffrey M. Holzbeierlein, MD, highlights the most promising data coming out of ASCO GU 2017

Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, on the most promising data showcased at ASCO GU.

Related Videos

video-image

Daniel Petrylak, MD, offers recommendations for bladder cancer patients

video-image

Daniel Petrylak, MD, on treating bladder cancer patients progressing on checkpoint inhibitors

video-image

Daniel Petrylak, MD, discusses the role of checkpoint inhibition therapy in urothelial carcinoma

video-image

Ulka N. Vaishampayan, MD, on challenges facing patients and providers

video-image

Ana Aparicio, MD, explains data and conclusions from her presentation at ASCO GU 2017

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugs

video-image

Robert B. Den, MD, give his thoughts on the most intriguing research presented at ASCO GU

video-image

Jeffrey M. Holzbeierlein, MD, highlights the most promising data coming out of ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, provides insight into data on resistance and advanced prostate cancer

video-image

Ana Aparicio, MD, on how to sequence commonly used agents in metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancer

video-image

Robert B. Den, MD, discusses the recent changes in radiation treatment for invasive bladder cancer

video-image

David J. McConkey, PhD, on which drugs have the highest potential to impact bladder cancer treatment

video-image

Mohamad E. Allaf, MD, on immunotherapies and renal cell carcinoma treatment algorithms

video-image

Jeffrey M. Holzbeierlein, MD, offers his opinion on interesting presentations from ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, explains the impact of CHAARTED and STAMPEDE

video-image

Matthew I. Milowsky, MD, outlines treating bladder cancer with checkpoint inhibitors

video-image

Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms

video-image

Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer

video-image

Freddie C. Hamdy, MD, offers his opinion on exciting research from ASCO GU 2017

video-image

David J. McConkey, PhD, on treating bladder cancer with checkpoint inhibitors

video-image

Mohamad E. Allaf, MD, provides insight into treating metastatic non-clear cell renal cell carcinoma

video-image

Ulka N. Vaishampayan, MD, on immunotherapies and renal cell carcinoma treatment algorithms

video-image

Jeffrey M. Holzbeierlein, MD, gives his perspective on treatment trends in urology for 2017

video-image

Neal D. Shore, MD, FACS, on where chemotherapy fits into prostate cancer treatment

video-image

Alexandra Drakaki, MD, PhD, shares highlights from sessions in bladder cancer at ASCO GU 2017

video-image

Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes

video-image

Eric Jonasch, MD, on targeted therapies used to treat non-clear cell renal cell carcinoma

video-image

Aly-Khan Lalani, MD, shares the results of his ASCO GU 2017 poster session

video-image

Ana Aparicio, MD, on commercial AR-V7 tests and metastatic castrate-resistant prostate cancer

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, explains the influence of CHAARTED and STAMPEDE

video-image

Robert B. Den, MD, on which patients with low-risk prostate cancer should receive radiation

video-image

Freddie C. Hamdy, MD, on putting into practice what we’ve learned from the ProtecT study

video-image

David J. McConkey, PhD, provides information on treating bladder cancer with checkpoint inhibitors

video-image

Mohamad E. Allaf, MD, shares the most intriguing research presented at ASCO GU 2017

video-image

Eric Jonasch, MD, on approaches to consider with metastatic non-clear renal cell carcinoma

video-image

Aly-Khan Lalani, MD, offers feedback on using immunotherapies to treat renal cell carcinoma patients

video-image

Ana Aparicio, MD, discusses where chemotherapy fits in regard to prostate cancer treatment

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines

video-image

Robert B. Den, MD, on the QOL differences between clinically localized prostate cancer patients

video-image

Freddie C. Hamdy, MD, elaborates on factors from the ProtecT study

video-image

David J. McConkey, PhD, on non-invasive imaging and monitoring metastatic bladder cancer

video-image

Mohamad E. Allaf, MD, on helping non-metastatic renal cell carcinoma patients with adjuvant therapy

video-image

Ulka N. Vaishampayan, MD, on metastatic renal cell carcinoma patients and chemotherapy

video-image

Jeffrey M. Holzbeierlein, MD, on the impact of his data presented at ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, on metastatic castration-resistant prostate cancer patients

video-image

Alexandra Drakaki, MD, PhD, on what we need to know about checkpoint inhibitors and bladder cancer

video-image

Matthew I. Milowsky, MD, on the role of genomics in understanding heterogeneity in bladder cancer

video-image

Eric Jonasch, MD, on treating non-metastatic renal cell carcinoma patients with adjuvant therapy

video-image

Aly-Khan Lalani, MD, examines the integration of immunotherapies for renal cell carcinoma treatment

video-image

Ana Aparicio, MD, discusses the impact of CHAARTED and STAMPEDE on her treatment decisions

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patients

video-image

Robert B. Den, MD, on the recent adoption of radiation treatment for advanced prostate cancer

video-image

Freddie C. Hamdy, MD, informs us on the ProtecT study top line results

video-image

David J. McConkey, PhD, on the responses to immunotherapy for varied bladder cancer subtypes

video-image

David J. McConkey, PhD, on the influence of genomics for the treatment of bladder cancer subtypes

video-image

Mohamad E. Allaf, MD, on non-metastatic renal cell cancer patients and adjuvant therapy

video-image

Ulka N. Vaishampayan, MD, provides her opinion on the most interesting research at ASCO GU 2017

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial test

video-image

Neal D. Shore, MD, FACS, on the impact of an AR-V7 commercial test

video-image

Jeffrey M. Holzbeierlein, MD, summarizes data and conclusions from his presentation at ASCO GU 2017

video-image

Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer

video-image

Alexandra Drakaki, MD, PhD, describes her work with microRNA and the potential clinical implications

video-image

Matthew I. Milowsky, MD, shares highlights from his lecture on urothelial carcinoma

video-image

Eric Jonasch, MD, on which non-metastatic renal cell cancer patients should receive adjuvant therapy

video-image

Aly-Khan Lalani, MD, provides feedback on which ASCO GU research presentations were most intriguing

video-image

Ana Aparicio, MD, on metastatic castration-resistant prostate cancer patients and chemotherapy

video-image

Robert B. Den, MD, considers topics in the “Best of Journals: Prostate Cancer” panel discussion

video-image

Freddie C. Hamdy, MD, on how the design of the ProtecT study works

video-image

David J. McConkey, PhD, discusses how genomics helps us understand heterogeneity in bladder cancer

video-image

Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancer